Potential of DMXAA combination therapy for solid tumors

References

• Denekamp J. Vascular attack as a therapeutic strategy for cancer. CancerMetastasis Rev. 9(3), 267–282 (1990).
   Google Scholar
• Auerbach W Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther. 63, 265–311 (1994).
   PubMed Web of Science ®Google Scholar
• Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure-activity relationships for in Ova colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem 34(1), 217–222 (1991).
   Google Scholar
• •First report of the synthesis and antitumor activity of DMXAA.
   Google Scholar
• Rustin G, Galbraith S, Taylor N et al Impact on tumour perfusion measured by dynamic magnetic resonance imaging (IVIRI), in the Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Ann. Oncol 9, 126 (1998).
   Google Scholar
• •First report of a clinical effect of DMXAA on tumor blood flow.
   Google Scholar
• Jameson MB, Thompson PI, Baguley BC et al Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol 19, 182a (2000).
   Google Scholar
• •First report of a Phase I clinical trial DMXAA.
   Google Scholar
• Starnes CO. Coley's toxins in perspective. Nature 357, 11–12 (1992).
   PubMed Web of Science ®Google Scholar
• Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother. 50, 391–396 (2001).
   PubMed Web of Science ®Google Scholar
• Old U. Tumor necrosis factor (TNF). Science 230, 630–632 (1985).
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old L,J, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 25, 3666–3670 (1975).
   Google Scholar
• Lienard D, Ewalenko P, Delmotte P, Renard JJ, Lejeune E High-dose recombinant tumor necrosis factor-CL in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.' Gun. aryl 10, 52–60 (1992).
   Google Scholar
• MacPherson GG, North RJ. Endotoxin- mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer hnmunol. Immunother 21(3), 209–216 (1986).
   Google Scholar
• Pimm MV, Gribben SJ, Morris TM. Influence of recombinant tumour necrosis factor-a on blood flow and antibody localisation in human tumour xenografts in nude mice. J. Cancer Res. Clin. Oncol 117(6), 543–548 (1991).
   Google Scholar
• Smith GP, Calveley SB, Smith MJ, Baguley BC. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur j Cancer Clin. Oncol 23, 1209–1212 (1987).
   Google Scholar
• Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor-a on Colon 38 tumors in mice. Eur. Cancer Clin. Oncol 25, 263–269 (1989).
   Google Scholar
• Plowman J, Narayanan VL, Dykes D et al Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep. 70,631-638 (1986).
   Google Scholar
• Evelhoch JL, Bissery M-C, Chabot GG et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4749–4755 (1988).
   PubMed Web of Science ®Google Scholar
• ZWi U, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J. Nall Cancer Inst. 81, 1005–1013 (1989).
   Google Scholar
• •Relationship of duration of tumor blood inhibition and the induction of tumor necrosis.
   Google Scholar
• Mace KF, Hornung RL, Wiltrout RII, Young HA. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose-dependency and therapeutic efficacy against murine renal cancer. Cancer Res. 50(6), 1742–1747 (1990).
   Google Scholar
• Kerr DJ, Kaye SB. Flavone acetic acid — preclinical and clinical activity. Eurj Cancer Clin. aryl 25, 1271–1272 (1989).
   PubMed Web of Science ®Google Scholar
• ZWi U, Baguley BC, Gavin JB, Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res. 6, 79–85 (1994).
   PubMed Web of Science ®Google Scholar
• •First report of effect of DMXAA on tumor blood flow.
   Google Scholar
• Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. J. Med. Chem. 33, 1375–1379 (1990).
   Google Scholar
• Lash CJ, Li AE, Rutland M, Baguley BC, Zwi L,J, Wilson WR. Enhancement of the antitumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br.Cancer 78, 439–445 (1998).
   Google Scholar
• •First report on combined effects of DMXAA and serotonin on tumor blood flow.
   Google Scholar
• Pedley RB, Sharma SK, Boxer GM et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59(16), 3998–4003 (1999).
   Google Scholar
• •First report of synergy between DMXAA and antibody-directed enzyme prodrug therapy.
   Google Scholar
• Sum BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)Technetium-labeled 2,2 --(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (Tc-99m-labeled HL-91; Prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res. 60(16), 4582–4588 (2000).
   Google Scholar
• •First report of the use of scintigraphic imaging of tumor hypo:oda induced by DMXAA.
   Google Scholar
• Philpott M, Baguley BC, Ching L-M. Induction of tumour necrosis factor-a by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36, 143–148 (1995).
   Google Scholar
• ••First report of in vivo induction of TNFby DMXAA.
   Google Scholar
• Ching L-M, Xu Z-F, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and antitumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. BE Cancer72, 339–343 (1995).
   Google Scholar
• •First report of the activity of DMXAA combined with thalidomide.
   Google Scholar
• Cao Z, Joseph WR, Browne WL et al Thalidomide increases both intra-tumoural tumour necrosis factor-a production and antitumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. BE Cancer80(5–6), 716–723 (1999).
   Google Scholar
• Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethyliamthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59(14), 3304–3307 (1999).
   Google Scholar
• •First use of gene knockout mice to investigate the role of TNF in the action of DMXAA.
   Google Scholar
• Zhao L, Baguley BC, Kestell P, Ching L-M. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. Cancer (2002) (In Press).
   Google Scholar
• •First demonstration that TNF induction is important for host toxicity as well as for antitumor activity
   Google Scholar
• Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor-a messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 54, 870–872 (1994).
   PubMed Web of Science ®Google Scholar
• •First report of a species difference in the actions of flavone acetic acid and DMXAA.
   Google Scholar
• Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi U. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine — evidence for a vascular mechanism. Eur. j Cancer 27 (4), 482–487 (1991).
   Google Scholar
• Ludford RJ. Cokhicine in the experimental chemotherapy of cancer. j Natl Cancer Inst. 6, 411–441 (1945).
   Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids — antivascular effects in a murine tumour. Eur j Cancer 29A, 1320–1324 (1993).
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. The effect of Vinca alkaloids on tumour blood flow. Adv. Exp. Med. Biol. 345, 417–422 (1994).
   PubMedGoogle Scholar
• Baguley BC, Zhuang L, Kestell P Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine and colchicine — relation to vascular effects. Oncol Res. 9(2), 55–60 (1997).
   Google Scholar
• •First report that DMXAA induces the release of the vasoactive agent serotonin into plasma.
   Google Scholar
• Schiff PB, Pant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 277,665–667 (1979).
   PubMed Web of Science ®Google Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57(10), 1829–1834 (1997).
   Google Scholar
• Stratford M, Folkes L, Galbraith S et al Phase I pharmacokinetic and toxicity study of weekly iv. combretastatin A4 phosphate (CA4P). Clin. Cancer Res. 6, S280 (2000).
   Google Scholar
• Ching L-M, Cao Z, Kieda C, Swain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. BE Cancer86, 1937-1942 (2002).
   Google Scholar
• ••First report of a direct effect of DMXAAon tumor vascular endothelial cells.
   Google Scholar
• Kestell P, Zhao L, Jameson M, Stratford MRL, Folkes LK, Baguley BC. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin. Chim. Acta 314, 159–166 (2001).
   Google Scholar
• •First report that DMXAA induces release of the vasoactive agent serotonin in cancer patients.
   Google Scholar
• Yi ES, Ulich TR. Endotoxin, interleukin-1 and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am j Pallid 140(3), 659–663 (1992).
   Google Scholar
• Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51(1), 77–81 (1991).
   Google Scholar
• •First report that DMXAA induces release of the vasoactive agent nitric oxide in mice.
   Google Scholar
• Philpott M, Ching LM, Baguley BC. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur.j Cancer37, 1930-1937 (2001).
   Google Scholar
• ••First report that DMXAA requires asecond signal for in iinv TNF induction.
   Google Scholar
• Ching LM, Joseph WR, Baguley BC. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. BE Cancer66(1), 128–130 (1992).
   Google Scholar
• Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of La kinase- 13. Nature 396 (6706), 77–80 (1998).
   Google Scholar
• Pedley RB, Boden JA, Boden R et al Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 56(14), 3293–3300 (1996).
   Google Scholar
• •First report of synergy between DMXAA and radioimmunotherapy.
   Google Scholar
• Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy — evaluation of tubulin binding agents. BE j Cancer74, S86—S88 (1996).
   Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7), 1408–1416 (1998).
   Google Scholar
• Tannock IF. Tumor physiology and drug resistance. Lancet 351, 9–16 (1998).
   PubMedGoogle Scholar
• Pruijn FB, van Daalen M, Holford NHG, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol 39, 541–546 (1997).
   Google Scholar
• •First report of synergy between DMXAA and a cytotmdc drug.
   Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 40(4), 497–503 (2001).
   PubMed Web of Science ®Google Scholar
• Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B — an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free. Raclic. Res. Commun. 17, 221–237 (1992).
   Google Scholar
• Wilson WR, Li AE, Cowan DSM, Sum BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Int. J Racliat. Oncol Biol. Phys. 42(4), 905–908 (1998).
   Google Scholar
• ••First report of synergy between DMXAAand radiotherapy.
   Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Racliat. Res. 156, 503–509 (2001).
   Google Scholar
• Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J Racliat. Oncol Biol. Phyc. 29, 373–377 (1994).
   Google Scholar
• •First report of synergy between DMXAA and bioreductive drugs.
   Google Scholar
• Wilson WR, Pruijn FB. Hypoxia-activated prodrugs as antitumour agents: strategies for maximising tumour cell killing. Clin. Exp. Pharmacol Physiol 22, 881–885 (1995).
   PubMed Web of Science ®Google Scholar
• Wilson WR, Denny WA, Pullen SM et al Tertiary amine Noxides as bioreductive drugs: DACA Noxide, nitracrine Noxide and AQ4N. U Cancer74, S43—S47 (1996).
   Web of Science ®Google Scholar
• Vincent PW, Roberts BJ, Elliott WL, Leopold WR. Chemotherapy with DMXAA (5,6-dimethylxanthenone-4-acetic acid) in combination with CI-1010 (1H-imidazole-1-ethanol,alpha-II (2-bromoethy0 amino] methyl] -2-nitro-, mono - hydrobromide (R isomer)) against advanced stage murine colon carcinoma 26. Oncol Rep. 4(1), 143–147 (1997).
   Google Scholar
• Wilson WR, Vanzil P, Denny WA. Bis- bioreductive agents as hypoxia-selective cytotoxins — nitracrine N-oxide. hit. j Racliat. Dna. Biol. Phys. 22, 693–696 (1992).
   Google Scholar
• Wilson WR, Sum BG, Denny WA et al. 5- nitro-4- (N,N- dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent — comparison with nitracrine. Racliat. Res. 131(3), 257–265 (1992).
   Google Scholar
• Sum BG, Denny WA, Wilson WR. Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? Int. J Racliat. Oncol Biol. Phys. 29, 311–315 (1994).
   Google Scholar
• Baguley BC. Novel strategies for overcoming multi-drug resistance in cancer. BioDrugs 16, 97–103 (2002).
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW Baldwin AS. TNF and cancer therapy-induced apoptosis — potentiation by inhibition of NF-KB. Science 274(5288), 784–787 (1996).
   PubMed Web of Science ®Google Scholar
• Wilson WR, Baguley BC. Combination of the antivascular agent DMXAA with radiation and chemotherapy. int. j Racliat. Oncol Biol. Phys. 46, 706 (2000).
   Google Scholar
• Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J Cancer99(1), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Pedley RB, Begent RII, Boden JA, Boxer GM, Boden R, Keep PA. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. liiLj Cancer57(6), 830–835 (1994).
   Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the antitumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int. J Hyperthermia 17(6), 508–519 (2001).
   Google Scholar
• •First report of synergy between DMXAA and hyperthermia.
   Google Scholar
• Van MW, Wielockx B, Mahieu T et al. HSP70 protects against TNF-induced lethal inflammatory shock. immunity 16(5), 685–695 (2002).
   Google Scholar
• Cao Z, Baguley BC, Ching L-M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61, 1517–1521 (2001).
   Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Calabrese L, Resztak K Thalidomide revisited: pharmacology and clinical applications. EVI Opin. Invest* Drugs 7 (1998).
   Google Scholar
• Eisen T, Roshoff C, Vaughan MM. Anti- angiogenic treatment of metatstatic melanoma, renal cell, ovarian and breast cancers with thalidomide: a Phase II study. Pax. Am. Sx. Clin. Oncol. 17, 441a (1998).
   Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes. J. Exp. Med. 173(3), 699–703 (1991).
   Google Scholar
• Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-a and enhancement of antitumour activity. Br. J Cancer78, 336–343 (1998).
   Google Scholar
• Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-x.13 activity by thalidomide through suppression of I-0 kinase activity. J Chem. 276, 22382–22387 (2001).
   Google Scholar
• Shannon EJ, Sandoval E Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-a by mononuclear cells. Immunopharmacol Immunotoxicol 18(1), 59–72 (1996).
   PubMed Web of Science ®Google Scholar
• Kestell P, Zhao L, Baguley BC et al. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-actic acid (DMXAA) in mice by thalidomide. Cancer Chemother. Pharmacol 46, 135–141 (2000).
   Google Scholar
• Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21(1A), 93–102 (2001).
   Google Scholar
• Cater DB, Petrie A, Watkinson DA. Effect of 5-hydroxytryptamine and cyproheptadine on tumour blood flow. Estimation by rate of cooling after microwave diathermy. Acta Racliolog. Ther. Phys. Biol. 3, 109–128 (1965).
   Google Scholar
• Baguley BC, Cole G, Thomsen LL, Zhuang L. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol 33, 77–81 (1993).
   Google Scholar
• •First report on synergy between DMXAA and serotonin.
   Google Scholar
• Zhao L, Kestell P, Philpott M, Ching L- M, Zhuang L, Baguley BC. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol 47, 491–497 (2001).
   Google Scholar
• •First report on synergy between DMXAA and the serotonin receptor antagonist cyproheptadine.
   Google Scholar
• Ramu A, Ramu N. Reversal of multi-drug resistance by phenothiazines and structurally related compounds. Cancer Chemother. Pharmacol 30(3), 165–173 (1992).
   Web of Science ®Google Scholar
• Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80) - mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res. 61(5), 1948–1956 (2001).
   Google Scholar
• •First report of synergy between DMXAA and gene therapy.
   Google Scholar
• Simm BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the aintitumor activity of chemotherapeutic drugs by antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol (2002) (In Press).
   Google Scholar